Review article · 2014

Contemporary phase III clinical trial endpoints in advanced ovarian cancer: assessing the pros and cons of objective response rate, progression-free survival, and overall survival

James Tate Thigpen

Gynecologic Oncology, 136(1), 121–129 · Published 25 October 2014 · DOI 10.1016/j.ygyno.2014.10.010

View at the publisherCite this paper

In brief

“Contemporary phase III clinical trial endpoints in advanced ovarian cancer: assessing the pros and cons of objective response rate, progression-free survival, and overall survival” is a 2014 review article by James Tate Thigpen, published in Gynecologic Oncology. OpenAlex counts 15 citations as of 22 November 2026. The publisher's version is not open access, and OpenAlex records no free legal copy.

Citations
15
Most cited in
2017 (3)
Field-weighted impact
0.27
References
66
Authors
1

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Thigpen, J. T. (2014). Contemporary phase III clinical trial endpoints in advanced ovarian cancer: assessing the pros and cons of objective response rate, progression-free survival, and overall survival. Gynecologic Oncology, 136(1), 121–129. https://doi.org/10.1016/j.ygyno.2014.10.010

MLA 9

Thigpen, James Tate. “Contemporary phase III clinical trial endpoints in advanced ovarian cancer: assessing the pros and cons of objective response rate, progression-free survival, and overall survival.” Gynecologic Oncology, vol. 136, no. 1, 2014, pp. 121–129. https://doi.org/10.1016/j.ygyno.2014.10.010.

Chicago

Thigpen, James Tate. 2014. “Contemporary phase III clinical trial endpoints in advanced ovarian cancer: assessing the pros and cons of objective response rate, progression-free survival, and overall survival.” Gynecologic Oncology 136 (1): 121–129. https://doi.org/10.1016/j.ygyno.2014.10.010.

Harvard

Thigpen, J. T. (2014) ‘Contemporary phase III clinical trial endpoints in advanced ovarian cancer: assessing the pros and cons of objective response rate, progression-free survival, and overall survival’, Gynecologic Oncology, 136(1), pp. 121–129. doi:10.1016/j.ygyno.2014.10.010.

IEEE

J. T. Thigpen, “Contemporary phase III clinical trial endpoints in advanced ovarian cancer: assessing the pros and cons of objective response rate, progression-free survival, and overall survival,” Gynecologic Oncology, vol. 136, no. 1, pp. 121–129, 2014, doi: 10.1016/j.ygyno.2014.10.010.

BibTeX

@article{thigpen2014contemporary,
  title     = {{Contemporary phase III clinical trial endpoints in advanced ovarian cancer: assessing the pros and cons of objective response rate, progression-free survival, and overall survival}},
  author    = {Thigpen, James Tate},
  journal   = {Gynecologic Oncology},
  year      = {2014},
  volume    = {136},
  number    = {1},
  pages     = {121--129},
  doi       = {10.1016/j.ygyno.2014.10.010},
  url       = {https://doi.org/10.1016/j.ygyno.2014.10.010}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Citations by year

YearCitationsShare of the best year
201522
201622
201733
201811
201911
202011
202322
202411
202511
202611

Its field-weighted citation impact is 0.27: it has been cited 0.27 times as often as the average work of the same field, type and year (1.00 is the world average).

Topic and keywords

Health Sciences › Medicine › Oncology › Ovarian cancer diagnosis and treatment

  • advanced ovarian cancer
  • clinical trial endpoints
  • objective response rate
  • progression-free survival
  • overall survival
  • post-progression therapy
  • RECIST
  • surrogate endpoints

Work with this paper

Most-cited papers in Medicine

All highly cited Medicine papers

Questions about this paper

How do I cite this paper in APA style?

Thigpen, J. T. (2014). Contemporary phase III clinical trial endpoints in advanced ovarian cancer: assessing the pros and cons of objective response rate, progression-free survival, and overall survival. Gynecologic Oncology, 136(1), 121–129. https://doi.org/10.1016/j.ygyno.2014.10.010

How many times has this paper been cited?

15 times, according to OpenAlex on 22 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

OpenAlex records no free legal copy. Check your library's access, the authors' pages or a repository, or ask the corresponding author for a copy.

Who wrote this paper?

James Tate Thigpen.

What is the DOI of this paper?

10.1016/j.ygyno.2014.10.010, permanently at https://doi.org/10.1016/j.ygyno.2014.10.010. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 22 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.